Dr. Sam Abbassi, MD, MS

Dr. Abbassi practices at Prime Eye Care Specialists, Inc. in West Hills, California.

Dr. Abbassi's NPI, 1881937720, was assigned on March 28, 2013. Dr. Abbassi graduated from Rush Medical College in 2013. Dr. Abbassi holds California license A133231.

Dr. Abbassi's primary practice is Prime Eye Care Specialists, Inc., at 7345 Medical Center Dr Ste 320, West Hills, CA 91307-1962. The practice phone is (818) 953-0093.

Dr. Abbassi's primary practice is Prime Eye Care Specialists, Inc. in West Hills, California. The medical group on file is Southern California Permanente Medical Group. Dmand AI also links Dr. Abbassi to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Abbassi practices, 3 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Abbassi's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Abbassi is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Abbassi's licenses on file in 4 states: California, South Dakota, Iowa and Nebraska.

Dmand AI lists age-related macular degeneration, cataract, conjunctivitis, dry eye, glaucoma, hereditary corneal conditions, hypertensive retinopathy and inflammation of iris among the conditions Dr. Abbassi treats.

CMS data shows 6,176 Medicare services from Dr. Abbassi across 15 procedure codes in 2024, for 780 Medicare patients. Medicare paid $1,190,937 for them. Every service was in an office.

CMS counts 780 Medicare patients who saw Dr. Abbassi in 2026. The largest group is 75 to 84, with 300 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 24% are also on Medicaid. Their average risk score is 1.47, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Abbassi's median patient age at 72, with 53% women.

In 2026, Dr. Abbassi wrote 367 Medicare Part D claims for 110 patients. 65% of them were for generic drugs. CMS names the drug for 266 of them, across 8 drugs with 11 or more claims each, at $5,569 in total drug cost. In 2023, CMS named 126 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Abbassi for performance year 2026, reported as part of a group. Dr. Abbassi accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 7 papers to Dr. Abbassi, published from 2013 to 2018. The most frequent topics are Collagen Type X, Mice, Transgenic and Bone and Bones. Dr. Abbassi has published most often in Eur J Ophthalmol. Dr. Abbassi's most frequent co-authors are Elad Moisseiev, MD, Sumeer Thinda, MD and Juan Carlos De Rivero Vaccari, MD, PhD.

Dmand AI links Dr. Abbassi to 1 clinical trial. Conditions studied include Macular Degeneration and Retinal Degeneration. Open Payments lists research payments to Dr. Abbassi that name 1 trial.

CMS Open Payments shows 18 general payments to Dr. Abbassi from 7 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 100% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $299. It also lists 8 research payments totaling $2,592 in 2019, naming 1 clinical trial.

Dr. Abbassi graduated from Rush Medical College in 2013.

Dr. Abbassi is in network with 16 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.